Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ursula Hempstead

Pediatrics Roseville, CA Medical Doctor

NPI 1134291966 CMS profile 1192663

151 N Sunrise Ave Ste 1309, Roseville, CA 95661

Open in the dashboard

General payments

$1,930

101 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ursula Hempstead of Roseville, CA is reported in the CMS Open Payments database as having received $1,930 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $232 12
2024 General $169 9
2023 General $279 15
2022 General $288 15
2021 General $656 33
2020 General $306 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ursula Hempstead
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ursula Hempstead were reported at $232. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ursula Hempstead Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $306 $49 $22–$110 $114
2021 $656 $68 $27–$158 $132
2022 $288 $77 $30–$173 $149
2023 $279 $88 $33–$190 $160
2024 $169 $94 $34–$206 $164
2025 $232 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $275 13 payments
  2. Biohaven Pharmaceuticals, Inc. $223 15 payments
  3. GlaxoSmithKline, LLC. $206 10 payments
  4. Merck Sharp & Dohme Corporation $166 9 payments
  5. Lilly USA, LLC $132 8 payments
  6. Regeneron Healthcare Solutions, Inc. $122 1 payment
  7. Biohaven Pharmaceutical Holding Company Ltd. $94 5 payments
  8. AbbVie, Inc. $85 5 payments
  9. kaleo, Inc. $76 5 payments
  10. Allergan Inc. $72 4 payments
  11. Other $479 26 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,930 101 payments
Products named General payments · program years 2020–2025
  1. NURTEC ODT $317 20 payments
  2. Ozempic $198 10 payments
  3. RYBELSUS $198 10 payments
  4. GARDASIL 9 $166 9 payments
  5. DUPIXENT $122 1 payment
  6. BEXSERO $118 6 payments
  7. VAXNEUVANCE $111 6 payments
  8. VAXELIS $95 5 payments
  9. SHINGRIX $86 4 payments
  10. PNEUMOVAX 23 $77 4 payments
  11. Other $1,282 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record